King Needs Second Trial In Order To Get Pediatric Extension for Altace
This article was originally published in The Pink Sheet Daily
The company has until October 2008 to complete another study after initial FDA rejection.
You may also be interested in...
New formulation from Arrow would allow King to extend the life of its ramipril brand.
Patent infringement litigation between the two companies is ongoing.
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.